Pfizer’s Seagen bet sours further; China debate continues to heat up; and morenews2026-06-27T10:00:25+00:00June 27th, 2026|Endpoints News|
Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and morenews2026-06-20T10:00:51+00:00June 20th, 2026|Endpoints News|
Biopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and morenews2026-06-13T10:00:11+00:00June 13th, 2026|Endpoints News|
Lawmakers propose China restrictions; #ASCO26 recap; and morenews2026-06-06T10:00:31+00:00June 6th, 2026|Endpoints News|
Can AI do scientific research?; The ‘magic bullet’ search has faded in immunotherapy; and more news2026-05-30T10:00:08+00:00May 30th, 2026|Endpoints News|
Inside Makary’s ouster; Another win for Lilly’s triple-G; and morenews2026-05-23T10:00:21+00:00May 23rd, 2026|Endpoints News|
Makary resigns; Biogen reports Alzheimer’s data; and morenews2026-05-16T10:00:39+00:00May 16th, 2026|Endpoints News|
Biotech’s new company model; The super poop behind a startup launch; and morenews2026-05-09T10:00:14+00:00May 9th, 2026|Endpoints News|
Bristol Myers’ pivotal year; Should AI be swinging bigger?; and morenews2026-05-02T10:00:47+00:00May 2nd, 2026|Endpoints News|
Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and morenews2026-04-25T10:00:19+00:00April 25th, 2026|Endpoints News|
